TMDX— AI Stock Forecast & Price Targets
Published 7/28/2026 · A free sample of K3vl4r’s AI-powered analysis.
Kronos price forecasts, scored fundamentals & technicals, and a multi-horizon plan.
View the live TMDX price forecast →
TMDX's elite underlying metrics (45% ROE, 59% GM) and long-term catalysts like European expansion and kidney OCS launch remain compelling, but near-term valuation is binary pending August 4 earnings confirmation of operational recovery from Q1 margin collapse. Current price action shows range-bound behavior between $65-$75 with no clear breakout above $80, while forecast bands suggest limited upside without earnings validation.
Wait for August 4 earnings; price must close above $80 to break out of range-bound behavior. If Q2 operating margins recover from 7.6% and FCF turns positive, consider a small position at $75-$80. Invalidation: below $65 or negative FCF confirmation.
Assume earnings confirm operational recovery (Q2 margin rebound to >10%, FCF positive). Target $90 as base with 10% upside potential over 3-6 months, driven by European expansion and kidney OCS launch. Change of mind: if margins remain below 10% or debt increases further without revenue growth.
Terminal thesis hinges on successful European rollout (2027) and kidney OCS commercialization (late 2026/early 2027), which could diversify revenue beyond liver. Long-term risk is regulatory shifts in organ reimbursement, but the core technology platform remains defensible with elite unit economics.
Revenue growth is strong (30% TTM) but Q1 operating margin collapsed to 7.6% from 23.2%, with negative FCF (-$12M) signaling temporary capex headwinds or structural issues. Balance sheet shows $461M cash cushion and $863M debt, while ROE (45%) and gross margins (59%) remain elite. Capital allocation is focused on NOP logistics scale-up ($344M investment), but revenue concentration in liver OCS (80% of business) creates vulnerability. The market prices trajectory over trailing metrics rather than forward potential.
Price has been range-bound between $65-$75 since May 2026, with no sustained breakout above $80 despite bullish narrative. Current price ($74.28) is near the lower end of the forecast band (actual: $73.85), while the model's high/low bands show limited upside potential without earnings confirmation. The chart shows a 1-day downtrend (-0.57%) and RSI at 52.61, indicating neutral momentum. Forecast bands suggest a narrow path to $90.641 (base) or $111.395 (bull), but directional accuracy is low (69% vs naive baseline), making these targets unreliable without earnings validation.
Recent news highlights conflicting analyst sentiment: Evercore ISI cut the price target to $90 while TD Cowen maintained a $120 target, reflecting uncertainty around Q1 margin collapse. The Motley Fool notes shares are down 45% but emphasizes long-term potential in organ transplantation logistics. However, the market is pricing binary outcomes on August 4 earnings—any positive FCF or margin recovery could trigger upside, while negative results would reinforce downside.
Get AI analysis on any stock
This is one of hundreds of Kronos AI reports — scored fundamentals & technicals, bull/base/bear price targets, a multi-horizon plan, and continuously-updated forecasts across the market. Create a free account to explore them all.
Create your free account →Already a member? Sign in · Join our Discord